Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan
Open Access
- 3 August 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (15) , 3801
Abstract
Several expedited regulatory review projects for innovative drugs and regenerative medical products have been developed in the US, the EU, and Japan. Each regulatory agency has elaborated an original regulatory framework and adopted regulatory projects developed by the other regulatory agencies. For example, the Food and Drug Administration (FDA) first developed the breakthrough therapy designation, and then the Pharmaceuticals and Medical Devices Agency (PMDA) and European Medicines Agency (EMA) introduced the Sakigake designation and the priority medicines (PRIME) designation, respectively. In addition, the necessity of the product being first development in Japan is the original feature of the Sakigake designation, while actively supporting the development of advanced-therapy medicinal products (ATMPs) by academia or small/medium-sized sponsors is the original feature of the PRIME; these particular features are different from the breakthrough therapy designation in the US. In this review article, flexible and expedited review processes for new drugs, and cell and gene therapies in the US, the EU, and Japan are described. Moreover, all the drugs and regenerative medical products that were granted conditional approval or Sakigake designation in Japan are listed and analyzed herein.Keywords
Funding Information
- Japan Society for the Promotion of Science (18K06779)
This publication has 11 references indexed in Scilit:
- Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in JapanClinical Therapeutics, 2018
- A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and BiologicsJAMA Oncology, 2018
- Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databasesInvestigational New Drugs, 2018
- New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy ProductsCurrent Gene Therapy, 2017
- Regulatory approval pathways for anticancer drugs in Japan, the EU and the USInternational Journal of Hematology, 2016
- Early market access of cancer drugs in the EUAnnals of Oncology, 2015
- Use of the conditional marketing authorization pathway for oncology medicines in EuropeClinical Pharmacology & Therapeutics, 2015
- Expediting Drug Development — The FDA's New “Breakthrough Therapy” DesignationNew England Journal of Medicine, 2013
- The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug RegulationClinical Cancer Research, 2011
- Conditional Approval and Approval Under Exceptional Circumstances as Regulatory Instruments for Stimulating Responsible Drug Innovation in EuropeClinical Pharmacology & Therapeutics, 2010